### Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

### VERTEX PHARMACEUTICALS INC / MA

Form 4

Common

Common

Stock

Stock

09/17/2008

September 19, 2008

FORM	1 4 HALTE	D CTATEC	S SECTIO	ITIES	· A	ND EV	~ <b>LL</b> A	NCE C	OMMISSION		PROVAL	
		UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB Washington, D.C. 20549 Number: 3235-02							3235-0287			
Check the if no lon	cer	box Expires:							January 31, 2005			
subject to Section Form 4 o Form 5	51 <b>A</b> 11 16. or	EMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES  oursuant to Section 16(a) of the Securities Exchange Act of 1934,							Estimated a burden hour response	verage		
obligation may con <i>See</i> Instraction 1(b).	ons Section 1	7(a) of the		ility H	old	ling Con	npany	y Act of	1935 or Section	n		
(Print or Type	Responses)											
MUELLER PETER Symbol			er Name <b>and</b> Ticker or Trading					5. Relationship of Reporting Person(s) to Issuer				
			INC / M						(Chec	k all applicable	)	
(Last)	(Last) (First) (Middle) 3. Date of (Month/Da				Earliest Transaction ay/Year)				Director 10% Owner X Officer (give title Other (specify below)			
	EX CEUTICALS RATED, 130 W	/AVERLY	09/17/20	800						Innov.& Realiz	, CSO	
	(Street)		4. If Amer Filed(Mon			_	l		6. Individual or Jo Applicable Line) _X_ Form filed by O			
CAMBRID	GE, MA 02139	)							Form filed by M Person	Iore than One Re	porting	
(City)	(State)	(Zip)	Table	e I - Nor	n-D	erivative	Secur	ities Acq	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date 2A. Deemed (Month/Day/Year) Execution Date, if any (Month/Day/Year)			3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8)					Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
				Code	V	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)			
Common Stock	09/17/2008			M		2,400	A	\$ 9.07	88,790	D		

\$

(2) (3)

2,400 D

27.94 86,390

3,460

D

I

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $S^{(1)}$ 

401(k)

### Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

> 8. I De Sec (In

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option	\$ 9.07	09/17/2008		M	2,400	<u>(4)</u>	12/10/2013	Common Stock	2,400	

# **Reporting Owners**

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

MUELLER PETER C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY STREET CAMBRIDGE, MA 02139

EVP Drug Innov.& Realiz, CSO

# **Signatures**

Valerie L. Andrews, Attorney-In-Fact 09/19/2008

\*\*Signature of Reporting Person Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1.
- (2) Open market sales reported on this line occurred at a weighted average price of \$27.94 (range \$27.46 to \$28.40).
- (3) Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- (4) Fully vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Reporting Owners 2

# Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.